MX2022016355A - Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras. - Google Patents

Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras.

Info

Publication number
MX2022016355A
MX2022016355A MX2022016355A MX2022016355A MX2022016355A MX 2022016355 A MX2022016355 A MX 2022016355A MX 2022016355 A MX2022016355 A MX 2022016355A MX 2022016355 A MX2022016355 A MX 2022016355A MX 2022016355 A MX2022016355 A MX 2022016355A
Authority
MX
Mexico
Prior art keywords
methods
delaying
preventing
acquired resistance
inhibitors
Prior art date
Application number
MX2022016355A
Other languages
English (en)
Inventor
Mallika Singh
Jingjing Jiang
Yu Chi Yang
James W Evans
Christopher J Schulze
Original Assignee
Revolution Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revolution Medicines Inc filed Critical Revolution Medicines Inc
Publication of MX2022016355A publication Critical patent/MX2022016355A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente descripción se refiere a composiciones y métodos para el tratamiento de enfermedades o trastornos (p. ej. cáncer) con inhibidores bi-estéricos de mTOR en combinación con inhibidores de RAS. Específicamente, en algunas modalidades la presente descripción incluye composiciones y métodos para inducir la apoptosis de las células tumorales y/o para retardar, prevenir, o tratar la resistencia adquirida a inhibidores de RAS usando inhibidores de mTOR bi-estéricos.
MX2022016355A 2020-06-18 2021-06-16 Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras. MX2022016355A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063041071P 2020-06-18 2020-06-18
US202063062973P 2020-08-07 2020-08-07
US202063117417P 2020-11-23 2020-11-23
US202163134128P 2021-01-05 2021-01-05
US202163192976P 2021-05-25 2021-05-25
PCT/US2021/037679 WO2021257736A1 (en) 2020-06-18 2021-06-16 Methods for delaying, preventing, and treating acquired resistance to ras inhibitors

Publications (1)

Publication Number Publication Date
MX2022016355A true MX2022016355A (es) 2023-04-03

Family

ID=77022185

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016355A MX2022016355A (es) 2020-06-18 2021-06-16 Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras.

Country Status (12)

Country Link
US (1) US20230233569A1 (es)
EP (1) EP4168002A1 (es)
JP (1) JP2023530351A (es)
KR (1) KR20230042600A (es)
CN (1) CN115916194A (es)
AU (1) AU2021293228A1 (es)
BR (1) BR112022025550A2 (es)
CA (1) CA3183032A1 (es)
IL (1) IL299131A (es)
MX (1) MX2022016355A (es)
TW (1) TW202214253A (es)
WO (1) WO2021257736A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117715915A (zh) * 2021-04-09 2024-03-15 杭州英创医药科技有限公司 作为kras g12d抑制剂的杂环化合物
WO2022247760A1 (zh) * 2021-05-22 2022-12-01 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物，及其制备和治疗用途
WO2023179629A1 (zh) * 2022-03-22 2023-09-28 苏州泽璟生物制药股份有限公司 取代桥环类抑制剂及其制备方法和应用
WO2023199180A1 (en) * 2022-04-11 2023-10-19 Novartis Ag Therapeutic uses of a krasg12c inhibitor
WO2023220631A2 (en) * 2022-05-10 2023-11-16 H. Lee Moffitt Cancer Center And Research Institute Inc. Selective k-ras inhibitors for the enhancement of adoptive immunotherapies
TW202402277A (zh) * 2022-05-25 2024-01-16 美商銳新醫藥公司 以mtor抑制劑治療癌症之方法

Family Cites Families (318)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
DE69334100T2 (de) 1992-11-13 2007-07-19 Immunex Corp., Seattle Elk ligand, ein cytokin
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5516658A (en) 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
CA2148931A1 (en) 1993-10-01 1995-04-13 Jurg Zimmermann Pyrimidineamine derivatives and processes for the preparation thereof
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
EP1464706A3 (en) 1994-04-15 2004-11-03 Amgen Inc., HEK5, HEK7, HEK8, HEK11, EPH-like receptor protein tyrosine kinases
EP0682027B1 (de) 1994-05-03 1997-10-15 Novartis AG Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
EP2295415A1 (en) 1995-03-30 2011-03-16 OSI Pharmaceuticals, Inc. Quinazoline derivatives
EP0819129B1 (en) 1995-04-03 2000-08-02 Novartis AG Pyrazole derivatives and processes for the preparation thereof
CA2218503C (en) 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5650415A (en) 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
SI9620103A (sl) 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
AU1441497A (en) 1996-01-23 1997-08-20 Novartis Ag Pyrrolopyrimidines and processes for their preparation
JP3406763B2 (ja) 1996-01-30 2003-05-12 東レ・ダウコーニング・シリコーン株式会社 シリコーンゴム組成物
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE19629652A1 (de) 1996-03-06 1998-01-29 Thomae Gmbh Dr K 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19608588A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PT888353E (pt) 1996-03-15 2003-11-28 Novartis Ag Novas n-7-heterociclil-pirrolo¬2,3-d|pirimidinas e sua aplicacao
PL190489B1 (pl) 1996-04-12 2005-12-30 Warner Lambert Co Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
EP0907642B1 (en) 1996-06-24 2005-11-02 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
TR199900048T2 (xx) 1996-07-13 1999-04-21 Glaxo Group Limited Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
ES2186908T3 (es) 1996-07-13 2003-05-16 Glaxo Group Ltd Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas.
HUP9903014A3 (en) 1996-07-18 2000-08-28 Pfizer Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
EP1947183B1 (en) 1996-08-16 2013-07-17 Merck Sharp & Dohme Corp. Mammalian cell surface antigens; related reagents
US6153609A (en) 1996-08-23 2000-11-28 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP4242928B2 (ja) 1996-08-23 2009-03-25 ノバルティス アクチエンゲゼルシャフト 置換ピロロピリミジンおよびその製造方法
AU4779897A (en) 1996-10-02 1998-04-24 Novartis Ag Fused pyrazole derivatives and processes for their preparation
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
JP4205168B2 (ja) 1996-10-02 2009-01-07 ノバルティス アクチエンゲゼルシヤフト ピリミジン誘導体およびその製造法
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
CA2277100C (en) 1997-01-06 2005-11-22 Pfizer Inc. Cyclic sulfone derivatives
TR199901849T2 (xx) 1997-02-03 2000-02-21 Pfizer Products Inc. Arils�lfonilamino hidroksamik asit t�revleri.
EP0964864B1 (en) 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
CA2279863A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
NZ336836A (en) 1997-02-11 2001-02-23 Pfizer Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6150395A (en) 1997-05-30 2000-11-21 The Regents Of The University Of California Indole-3-carbinol (I3C) derivatives and methods
WO1999007701A1 (en) 1997-08-05 1999-02-18 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
ATE263147T1 (de) 1997-08-08 2004-04-15 Pfizer Prod Inc Derivate von aryloxyarylsulfonylamino hydroxyaminsäuren
JP2001520039A (ja) 1997-10-21 2001-10-30 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒト腫瘍壊死因子レセプター様タンパク質、ｔｒ１１，ｔｒ１１ｓｖ１およびｔｒ１１ｓｖ２
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
CA2319236A1 (en) 1998-02-09 1999-08-12 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
AU756838B2 (en) 1998-03-04 2003-01-23 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
HUP0103617A2 (hu) 1998-05-29 2002-02-28 Sugen, Inc. Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
WO2000002871A1 (en) 1998-07-10 2000-01-20 Merck & Co., Inc. Novel angiogenesis inhibitors
AU760020B2 (en) 1998-08-31 2003-05-08 Merck & Co., Inc. Novel angiogenesis inhibitors
DK1004578T3 (da) 1998-11-05 2004-06-28 Pfizer Prod Inc 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater
DE60028740T2 (de) 1999-03-30 2007-05-24 Novartis Ag Phthalazinderivate zur behandlung von entzündlichen erkrankungen
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
IL146482A0 (en) 1999-06-07 2002-07-25 Immunex Corp Tek antagonists
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
ATE376837T1 (de) 1999-07-12 2007-11-15 Genentech Inc Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen
UA72946C2 (uk) 1999-11-05 2005-05-16 Астразенека Аб Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
WO2001037820A2 (en) 1999-11-24 2001-05-31 Sugen, Inc. Ionizable indolinone derivatives and their use as ptk ligands
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2001062895A2 (en) 2000-02-24 2001-08-30 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
NZ521437A (en) 2000-02-25 2004-04-30 Immunex Corp Integrin antagonists suitable as inhibitors of angiogenesis
US6630500B2 (en) 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
ATE430742T1 (de) 2000-12-21 2009-05-15 Smithkline Beecham Corp Pyrimidinamine als angiogenesemodulatoren
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
CA2525717A1 (en) 2003-05-23 2004-12-09 Wyeth Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
AR045134A1 (es) 2003-07-29 2005-10-19 Smithkline Beecham Plc Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
PL1660458T3 (pl) 2003-08-15 2012-07-31 Novartis Ag 2,4-pirymidynodwuaminy stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego
WO2005055808A2 (en) 2003-12-02 2005-06-23 Genzyme Corporation Compositions and methods to diagnose and treat lung cancer
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
WO2006083289A2 (en) 2004-06-04 2006-08-10 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
ATE463486T1 (de) 2004-08-26 2010-04-15 Pfizer Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
WO2006044453A1 (en) 2004-10-13 2006-04-27 Wyeth Analogs of 17-hydroxywortmannin as pi3k inhibitors
EP1866339B8 (en) 2005-03-25 2021-12-01 GITR, Inc. Gitr binding molecules and uses therefor
LT2439273T (lt) 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20090012085A1 (en) 2005-09-20 2009-01-08 Charles Michael Baum Dosage forms and methods of treatment using a tyrosine kinase inhibitor
EP1981969A4 (en) 2006-01-19 2009-06-03 Genzyme Corp ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER
US7888352B2 (en) 2006-12-07 2011-02-15 Piramed Limited Phosphoinositide 3-kinase inhibitor compounds and methods of use
US20100238571A1 (en) 2007-06-29 2010-09-23 Frissen Richard J Mirror optic system
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
CA2701292C (en) 2007-10-25 2015-03-24 Genentech, Inc. Process for making thienopyrimidine compounds
KR20110044992A (ko) 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＧＦ-β 길항제 다중-표적 결합 단백질
CN102149820B (zh) 2008-09-12 2014-07-23 国立大学法人三重大学 能够表达外源gitr配体的细胞
LT3023438T (lt) 2009-09-03 2020-05-11 Merck Sharp & Dohme Corp. Anti-gitr antikūnai
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
DK2688887T3 (en) 2011-03-23 2015-06-29 Amgen Inc DEHYDRATED tricyclic DUALINHIBITORER OF CDK 4/6 AND FLT3
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
EP2836482B1 (en) 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
WO2014113584A1 (en) 2013-01-16 2014-07-24 Rhode Island Hospital Compositions and methods for the prevention and treatment of osteolysis and osteoporosis
EP2970121B1 (en) 2013-03-15 2017-12-13 Araxes Pharma LLC Covalent inhibitors of kras g12c
WO2014143659A1 (en) 2013-03-15 2014-09-18 Araxes Pharma Llc Irreversible covalent inhibitors of the gtpase k-ras g12c
CA2944198C (en) 2013-04-26 2021-11-16 Indiana University Research & Technology Corporation Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2)
KR20160076519A (ko) 2013-10-10 2016-06-30 아락세스 파마 엘엘씨 Kras g12c 억제제
WO2015107493A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
EP3094629B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
WO2015191996A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
CN113620978A (zh) 2014-09-11 2021-11-09 加利福尼亚大学董事会 mTORC1抑制剂
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
WO2016049524A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US20160168108A1 (en) 2014-12-16 2016-06-16 Adt Pharmaceuticals, Inc. Method of treating or preventing ras-mediated diseases
TW201702232A (zh) 2015-04-10 2017-01-16 亞瑞克西斯製藥公司 經取代之喹唑啉化合物及其使用方法
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
WO2016176338A1 (en) 2015-04-30 2016-11-03 The Trustees Of Columbia University In The City Of New York Small molecule ras ligands
WO2016179558A1 (en) 2015-05-06 2016-11-10 The Regents Of The University Of California K-ras modulators
WO2016191328A1 (en) 2015-05-22 2016-12-01 Allosta Pharmaceuticals Methods to prepare and employ binding site models for modulation of phosphatase activity and selectivity determination
WO2016196591A1 (en) 2015-06-01 2016-12-08 Indiana University Research & Technology Corporation Protein tyrosine phosphatases or shp2 inhibitors and uses thereof
US10975080B2 (en) 2015-06-19 2021-04-13 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
CN107922388B (zh) 2015-06-19 2020-12-29 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
JP6878316B2 (ja) 2015-06-19 2021-05-26 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
MX2018000777A (es) 2015-07-22 2018-03-23 Araxes Pharma Llc Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c.
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356339A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058807A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017078499A2 (ko) 2015-11-06 2017-05-11 경북대학교 산학협력단 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
WO2017079723A1 (en) 2015-11-07 2017-05-11 Board Of Regents, The University Of Texas System Targeting proteins for degradation
WO2017079864A1 (en) 2015-11-12 2017-05-18 Hangzhou Yier Biotech Co., Ltd. Treatment of cancers related to chronically active ras
JP7015059B2 (ja) 2015-11-16 2022-02-15 アラクセス ファーマ エルエルシー 置換複素環式基を含む２－置換キナゾリン化合物およびその使用方法
US20170158702A1 (en) 2015-12-02 2017-06-08 Kyras Therapeutics, Inc. Multivalent ras binding compounds
WO2017100279A1 (en) 2015-12-09 2017-06-15 West Virginia University Chemical compound for inhibition of shp2 function and for use as an anti-cancer agent
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017106520A1 (en) 2015-12-16 2017-06-22 Adt Pharmaceuticals, Inc. Compounds, compositions and methods of treating cancer
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
EP3206357A1 (de) 2016-02-09 2017-08-16 Secunet Security Networks Aktiengesellschaft Einsatz eines nicht lokalen kryptographie-verfahrens nach authentifizierung
WO2017156397A1 (en) 2016-03-11 2017-09-14 Board Of Regents, The University Of Texas Sysytem Heterocyclic inhibitors of ptpn11
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
ES2863873T3 (es) 2016-05-18 2021-10-11 Mirati Therapeutics Inc Inhibidores de KRAS G12C
JP7044375B2 (ja) 2016-05-31 2022-03-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｐｔｐｎ１１の複素環式阻害剤
SG10202110874TA (en) 2016-06-07 2021-11-29 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
ES2810852T3 (es) 2016-06-14 2021-03-09 Novartis Ag Compuestos y composiciones para inhibir la actividad de shp2
CN109661229B (zh) 2016-06-29 2022-06-28 加利福尼亚大学董事会 用于治疗癌症的化合物和组合物
KR20230156174A (ko) 2016-07-12 2023-11-13 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
EP3269365A1 (en) 2016-07-14 2018-01-17 Friedrich-Alexander-Universität Erlangen-Nürnberg Kras inhibitor for use in treating cancer
EP3515916B1 (en) 2016-09-22 2023-06-07 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
EP3519402A1 (en) 2016-09-29 2019-08-07 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
CN110312711A (zh) 2016-10-07 2019-10-08 亚瑞克西斯制药公司 作为ras抑制剂的杂环化合物及其使用方法
TW201819386A (zh) 2016-10-24 2018-06-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
BR112019012263A2 (pt) 2016-12-15 2020-01-28 Univ California composições e métodos para tratar câncer
RS62456B1 (sr) 2016-12-22 2021-11-30 Amgen Inc Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva
US10988766B2 (en) 2017-01-06 2021-04-27 Oregon Health & Science University Compositions and methods used in diagnosing and treating colorectal cancer
CA3048340A1 (en) 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
CN110446709B (zh) 2017-01-23 2023-09-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
AU2018210196B2 (en) 2017-01-23 2022-06-02 Revolution Medicines, Inc. Pyridine compounds as allosteric SHP2 inhibitors
EP3573964A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
CN110382483A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的n-杂环化合物及其使用方法
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11059819B2 (en) 2017-01-26 2021-07-13 Janssen Biotech, Inc. Fused hetero-hetero bicyclic compounds and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
JOP20190186A1 (ar) 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
EA201992253A1 (ru) 2017-03-23 2020-03-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
CA3059943A1 (en) 2017-04-20 2018-10-25 The Regents Of The University Of California K-ras modulators
RU2019138161A (ru) 2017-05-02 2021-06-02 Революшн Медсинз, Инк. АНАЛОГИ РАПАМИЦИНА КАК ИНГИБИТОРЫ mTOR
AR111776A1 (es) 2017-05-11 2019-08-21 Astrazeneca Ab Heteroarilos inhibidores de las proteínas ras mutantes de g12c
US11318137B2 (en) 2017-05-17 2022-05-03 Vanderbilt University Quinazoline compounds as modulators of Ras signaling
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
WO2018218071A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
CA3063440A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Covalent inhibitors of kras
US11591336B2 (en) 2017-05-26 2023-02-28 D. E. Shaw Research, Llc Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
WO2019051084A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER
SG11202001499WA (en) 2017-09-08 2020-03-30 Amgen Inc Inhibitors of kras g12c and methods of using the same
EP3681879A1 (en) 2017-09-11 2020-07-22 Krouzon Pharmaceuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
WO2019055540A1 (en) 2017-09-13 2019-03-21 D.E. Shaw Research, Llc COMPOUNDS AS INHIBITORS OF RAS AND THEIR USE
EP3710439B1 (en) 2017-11-15 2023-02-15 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2019110751A1 (en) 2017-12-08 2019-06-13 Astrazeneca Ab Tetracyclic compounds as inhibitors of g12c mutant ras protein, for use as anti-cancer agents
US11466012B2 (en) 2018-01-10 2022-10-11 Allinky Biopharma Tetrahydroisoquinoline compounds
WO2019152454A1 (en) 2018-01-30 2019-08-08 Research Development Foundation Shp2 inhibitors and methods of use thereof
TW201942115A (zh) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
TW201942116A (zh) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
KR102614939B1 (ko) 2018-02-13 2023-12-19 블루레이 테라퓨틱스 (상하이) 컴퍼니 리미티드 피리미딘-융합고리 화합물 및 그의 제조방법과 용도
US20200392161A1 (en) 2018-02-21 2020-12-17 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
SG11202006778TA (en) 2018-03-02 2020-08-28 Otsuka Pharma Co Ltd Pharmaceutical compounds
BR112020019385A2 (pt) 2018-03-21 2021-03-30 Relay Therapeutics, Inc. Inibidores de shp2 fosfatase e métodos de uso dos mesmos
WO2019182960A1 (en) 2018-03-21 2019-09-26 Synblia Therapeutics, Inc. Shp2 inhibitors and uses thereof
EP3768680A1 (en) 2018-03-21 2021-01-27 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
WO2019204505A2 (en) 2018-04-18 2019-10-24 Theras, Inc. K-ras modulators with a vinyl sulfonamide moiety
WO2019204442A1 (en) 2018-04-18 2019-10-24 Theras, Inc. K-ras modulators with a cyanoacrylamide moiety
WO2019204449A1 (en) 2018-04-18 2019-10-24 Theras, Inc. K-ras modulators with a vinyl sulfone moiety
AU2019262979B2 (en) 2018-05-01 2023-07-06 Revolution Medicines, Inc. C26-linked rapamycin analogs as mTOR inhibitors
US20190336609A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
SG11202010822SA (en) 2018-05-02 2020-11-27 Navire Pharma Inc Substituted heterocyclic inhibitors of ptpn11
EP3788038B1 (en) 2018-05-04 2023-10-11 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11045484B2 (en) 2018-05-04 2021-06-29 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
TW202012415A (zh) 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
JP2021528368A (ja) 2018-05-10 2021-10-21 ユニヴァーシティー・オブ・ルイスヴィル・リサーチ・ファウンデイション・インコーポレーテッド Ｒａｓ腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法
WO2019217691A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
US20210214341A1 (en) 2018-05-25 2021-07-15 The Board Of Regents Of The University Of Texas System Substituted pyridinyl azetidinone derivatives for use in treating cancer and other diseases
US11096939B2 (en) 2018-06-01 2021-08-24 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US20210230300A1 (en) 2018-06-04 2021-07-29 Bayer Aktiengesellschaft Inhibitors of shp2
GB201809102D0 (en) 2018-06-04 2018-07-18 Univ Oxford Innovation Ltd Compounds
EP3802537A1 (en) 2018-06-11 2021-04-14 Amgen Inc. Kras g12c inhibitors for treating cancer
MX2020012261A (es) 2018-06-12 2021-03-31 Amgen Inc Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
US10972950B2 (en) 2018-07-20 2021-04-06 Qualcomm Incorporated Methods and apparatus for handover enhancements
EP3827009A4 (en) 2018-07-24 2022-04-27 Taiho Pharmaceutical Co., Ltd. HETEROBICYCLIC COMPOUNDS TO INHIBIT SHP2 ACTIVITY
US20210317127A1 (en) 2018-08-01 2021-10-14 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
US11518770B2 (en) 2018-08-06 2022-12-06 Purdue Research Foundation Sesquiterpenoid analogs
WO2020033413A2 (en) 2018-08-07 2020-02-13 Tosk, Inc. Modulators of ras gtpase
PE20211050A1 (es) 2018-08-10 2021-06-04 Navire Pharma Inc Inhibidores de ptpn11
MA51777A (fr) 2018-08-16 2021-04-21 Hoffmann La Roche Composés cycliques condensés
ES2961253T3 (es) 2018-08-31 2024-03-11 Mirati Therapeutics Inc Inhibidores de KRas G12C
AU2019338207A1 (en) * 2018-09-10 2021-04-29 Mirati Therapeutics, Inc. Combination therapies
US11459340B2 (en) 2018-09-18 2022-10-04 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
WO2020063760A1 (en) 2018-09-26 2020-04-02 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
WO2020065452A1 (en) 2018-09-29 2020-04-02 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of shp2
CA3113379A1 (en) 2018-09-29 2020-04-02 Novartis Ag Process of manufacture of a compound for inhibiting the activity of shp2
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
WO2020073945A1 (zh) 2018-10-10 2020-04-16 江苏豪森药业集团有限公司 双环类衍生物抑制剂、其制备方法和应用
TW202028183A (zh) 2018-10-10 2020-08-01 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
TW202033518A (zh) 2018-10-15 2020-09-16 美商美國禮來大藥廠 Kras g12c 抑制劑
KR102649419B1 (ko) 2018-10-17 2024-03-21 어레이 바이오파마 인크. 단백질 티로신 포스파타제 억제제
JP2022505835A (ja) 2018-10-24 2022-01-14 アラクセス ファーマ エルエルシー 腫瘍転移を阻害するためのｇ１２ｃ変異体ｋｒａｓタンパク質の阻害剤としての２－（２－アクリロイル－２，６－ジアザスピロ［３．４］オクタン－６－イル）－６－（１ｈ－インダゾール－４－イル）－ベンゾニトリル誘導体および関連化合物
CN117143079A (zh) 2018-11-06 2023-12-01 上海奕拓医药科技有限责任公司 一种螺芳环化合物及其应用
CN114751903B (zh) 2018-11-07 2023-09-15 上海凌达生物医药有限公司 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
KR102587544B1 (ko) 2018-11-09 2023-10-11 에프. 호프만-라 로슈 아게 축합 고리 화합물
JP2020090482A (ja) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
CA3117222A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
US20220000869A1 (en) 2018-11-23 2022-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of shp2 inhibitors for the treatment of insulin resistance
MX2021005924A (es) 2018-11-29 2021-06-30 Araxes Pharma Llc Compuestos y metodos de uso de los mismos para el tratamiento del cancer.
WO2020108590A1 (zh) 2018-11-30 2020-06-04 上海拓界生物医药科技有限公司 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
EA202190630A1 (ru) 2018-12-05 2021-10-11 Мирати Терапьютикс, Инк. Способы комбинированной терапии
WO2020132597A1 (en) 2018-12-21 2020-06-25 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
CN113365988B (zh) 2019-01-31 2023-10-03 贝达药业股份有限公司 Shp2抑制剂及其应用
CN113316574B (zh) 2019-01-31 2024-01-30 贝达药业股份有限公司 Shp2抑制剂及其应用
EP3924053A1 (en) 2019-02-12 2021-12-22 Novartis AG Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
CN113382731A (zh) 2019-02-12 2021-09-10 诺华股份有限公司 包含tno155和瑞博西尼的药物组合
MX2021009562A (es) 2019-02-12 2021-09-08 Novartis Ag Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1.
CN111647000B (zh) 2019-03-04 2021-10-12 勤浩医药（苏州）有限公司 吡嗪类衍生物及其在抑制shp2中的应用
JP7453989B2 (ja) 2019-03-05 2024-03-21 アストラゼネカ・アクチエボラーグ 抗癌剤として有用な縮合三環式化合物
AU2020232026A1 (en) 2019-03-07 2021-09-02 Merck Patent Gmbh Carboxamide-pyrimidine derivatives as shp2 antagonists
CA3135555C (en) 2019-04-02 2023-09-19 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors
JP2022527013A (ja) 2019-04-08 2022-05-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｈｐ２拮抗薬としてのピリミジノン誘導体
EP3967695B1 (en) 2019-04-22 2024-01-17 Betta Pharmaceuticals Co., Ltd 1-(7-(quinazolin-4-yl)-2,7-diazaspiro[3.5]nonan-2-yl)prop-2-en-1-one derivatives as kras inhibitors for the treatment of cancer
US20220227729A1 (en) 2019-05-21 2022-07-21 Bayer Aktiengesellschaft Identification and use of kras inhibitors
AU2020279287A1 (en) 2019-05-21 2021-12-16 InventisBio Co., Ltd. Heterocyclic compounds, preparation methods and uses thereof
CN114008035A (zh) 2019-06-14 2022-02-01 北京盛诺基医药科技股份有限公司 一种shp2磷酸酶变构抑制剂
WO2020259513A1 (en) 2019-06-24 2020-12-30 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of kras g12c
CN110256421A (zh) 2019-06-26 2019-09-20 微境生物医药科技(上海)有限公司 Kras-g12c抑制剂
BR112021024674A2 (pt) 2019-06-28 2022-05-31 Tuojie Biotech Shanghai Co Ltd Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
CN112300160A (zh) 2019-08-01 2021-02-02 上海奕拓医药科技有限责任公司 一种螺芳环化合物、其制备及应用
CN112341457A (zh) 2019-08-07 2021-02-09 北京加科思新药研发有限公司 Kras突变蛋白抑制剂
EP3772513A1 (en) 2019-08-09 2021-02-10 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening Shp2 inhibitors
CN112390797A (zh) 2019-08-15 2021-02-23 微境生物医药科技(上海)有限公司 新型螺环类K-Ras G12C抑制剂
WO2021031952A1 (zh) 2019-08-16 2021-02-25 劲方医药科技(上海)有限公司 氧代六元环并嘧啶类化合物，其制法与医药上的用途
GB201911928D0 (en) 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
CN114127053B (zh) 2019-09-06 2023-06-13 四川科伦博泰生物医药股份有限公司 一种取代吡嗪化合物、其制备方法和用途
US20220402916A1 (en) 2019-09-18 2022-12-22 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
WO2021061515A1 (en) 2019-09-23 2021-04-01 Synblia Therapeutics, Inc. Shp2 inhibitors and uses thereof
JP2022548792A (ja) 2019-09-24 2022-11-21 リレー セラピューティクス， インコーポレイテッド Ｓｈｐ２ホスファターゼ阻害剤並びにその作製方法及び使用方法
CN112552295A (zh) 2019-09-25 2021-03-26 北京加科思新药研发有限公司 Kras突变蛋白抑制剂
WO2021058018A1 (en) 2019-09-29 2021-04-01 Beigene, Ltd. Inhibitors of kras g12c
CN112724145A (zh) 2019-10-14 2021-04-30 杭州雷索药业有限公司 用于抑制shp2活性的吡嗪衍生物
WO2021081212A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
IL292438A (en) 2019-10-28 2022-06-01 Merck Sharp & Dohme Small molecules that inhibit the g12c mutant of kras
US20230023023A1 (en) 2019-10-31 2023-01-26 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
CN113286794B (zh) 2019-11-04 2024-03-12 北京加科思新药研发有限公司 Kras突变蛋白抑制剂
CA3159559A1 (en) * 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
EP4056563A4 (en) 2019-11-08 2024-02-21 Nanjing Sanhome Pharmaceutical Co Ltd COMPOUND USED AS SHP2 INHIBITOR AND ITS USE
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
EP4069301A1 (en) 2019-12-04 2022-10-12 Bayer Aktiengesellschaft Inhibitors of shp2
WO2021113595A1 (en) 2019-12-06 2021-06-10 Beta Pharma, Inc. Phosphorus derivatives as kras inhibitors

Also Published As

Publication number Publication date
BR112022025550A2 (pt) 2023-03-07
KR20230042600A (ko) 2023-03-28
EP4168002A1 (en) 2023-04-26
IL299131A (en) 2023-02-01
WO2021257736A1 (en) 2021-12-23
CA3183032A1 (en) 2021-12-23
AU2021293228A1 (en) 2023-02-09
US20230233569A1 (en) 2023-07-27
JP2023530351A (ja) 2023-07-14
TW202214253A (zh) 2022-04-16
CN115916194A (zh) 2023-04-04

Similar Documents

Publication Publication Date Title
MX2022016355A (es) Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
MX2020009773A (es) Terapia de combinacion.
MX2017013142A (es) Terapia combinada para tratar cáncer.
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
MX2016007351A (es) Terapia de combinacion para tratar cancer.
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
NZ736853A (en) Methods of treating cancer patients with farnesyl transferase inhibitors
EA201890730A1 (ru) Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
MX2022010082A (es) Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo.
WO2014144847A3 (en) Hspc-sparing treatments for rb-positive abnormal cellular proliferation
EP4140487A8 (en) Combination therapy for treating cancer
EP4085919A3 (en) Compositions and methods to treat cancer
MX2019003134A (es) Terapia de combinacion.
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
MX2019012176A (es) Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2020001727A (es) Terapia de combinacion.
AU2018271862A1 (en) Combination therapy